Sun Life Financial INC Has $265,000 Stake in Regeneron Pharmaceuticals, Inc. (REGN)
Sun Life Financial INC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3,275.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 540 shares of the biopharmaceutical company’s stock after acquiring an additional 524 shares during the quarter. Sun Life Financial INC’s holdings in Regeneron Pharmaceuticals were worth $265,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the company. Oppenheimer & Co. Inc. raised its position in shares of Regeneron Pharmaceuticals by 20.6% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock worth $3,441,000 after purchasing an additional 1,199 shares during the last quarter. Dupont Capital Management Corp bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $220,000. Blair William & Co. IL boosted its stake in Regeneron Pharmaceuticals by 4.8% in the 2nd quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock worth $841,000 after purchasing an additional 79 shares in the last quarter. Principal Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 2.4% during the 2nd quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock valued at $56,580,000 after purchasing an additional 2,646 shares during the last quarter. Finally, National Pension Service grew its position in Regeneron Pharmaceuticals by 10.8% during the 2nd quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after purchasing an additional 6,481 shares during the last quarter. Hedge funds and other institutional investors own 67.95% of the company’s stock.
In other news, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Robert E. Landry sold 526 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $472.19, for a total transaction of $248,371.94. Following the transaction, the senior vice president now directly owns 9,099 shares of the company’s stock, valued at $4,296,456.81. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 85,968 shares of company stock valued at $40,699,948. 10.80% of the stock is owned by company insiders.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded up 2.88% during mid-day trading on Monday, hitting $460.01. 316,859 shares of the stock were exchanged. The company has a market cap of $48.78 billion, a P/E ratio of 46.15 and a beta of 1.63. The stock’s 50-day moving average price is $468.97 and its 200-day moving average price is $447.18. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. The firm had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company’s revenue was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.82 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $14.93 earnings per share for the current fiscal year.
A number of analysts have weighed in on the stock. Piper Jaffray Companies restated an “overweight” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 27th. UBS AG dropped their target price on shares of Regeneron Pharmaceuticals from $535.00 to $500.00 and set a “buy” rating on the stock in a research note on Thursday, September 21st. Royal Bank Of Canada began coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $475.00 target price on the stock. Finally, Canaccord Genuity reiterated a “buy” rating and set a $522.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, September 11th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $489.35.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.